|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
87,040,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company. Co. is engaged in developing and commercializing targeted therapies for patients with genomically-defined cancers. Co.'s main product candidate, DAY101 (tovorafenib), is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor. Co.'s second product candidate, pimasertib, is an oral, highly-selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a well-characterized key signaling node in the RAS/mitogen-activated protein kinase pathway.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,475,454 |
2,244,684 |
Total Buy Value |
$0 |
$0 |
$14,978,328 |
$24,978,318 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
3 |
4 |
Total Shares Sold |
68,748 |
284,488 |
370,354 |
1,292,455 |
Total Sell Value |
$1,009,356 |
$4,598,978 |
$5,897,036 |
$12,396,555 |
Total People Sold |
4 |
5 |
5 |
7 |
Total Sell Transactions |
6 |
20 |
31 |
73 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Blavatnik Len |
Affiliate of 10% Owner |
|
2023-06-09 |
4 |
B |
$13.00 |
$9,999,990 |
D/D |
769,230 |
11,453,868 |
2.44 |
- |
|
Blackman Samuel C. |
Chief Medical Officer |
|
2023-06-05 |
4 |
AS |
$16.00 |
$19,664 |
D/D |
(1,229) |
1,234,363 |
|
- |
|
Bender Jeremy |
Chief Executive Officer |
|
2023-05-16 |
4 |
S |
$13.12 |
$40,732 |
D/D |
(3,104) |
1,179,484 |
|
- |
|
Blackman Samuel C. |
Chief Medical Officer |
|
2023-05-16 |
4 |
S |
$13.12 |
$9,081 |
D/D |
(692) |
1,235,592 |
|
- |
|
York Charles N Ii |
COO, CFO and Secretary |
|
2023-05-16 |
4 |
S |
$13.12 |
$12,532 |
D/D |
(955) |
264,798 |
|
- |
|
Bender Jeremy |
Chief Executive Officer |
|
2023-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,312 |
1,182,588 |
|
- |
|
Blackman Samuel C. |
Chief Medical Officer |
|
2023-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,624 |
1,236,284 |
|
- |
|
York Charles N Ii |
COO, CFO and Secretary |
|
2023-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,625 |
265,753 |
|
- |
|
Blackman Samuel C. |
Chief Medical Officer |
|
2023-03-10 |
4 |
AS |
$18.05 |
$180,484 |
D/D |
(10,000) |
1,233,660 |
|
- |
|
Bender Jeremy |
Chief Executive Officer |
|
2023-03-07 |
4 |
AS |
$20.01 |
$250,114 |
D/D |
(12,500) |
1,174,276 |
|
- |
|
Papanek Julie |
Director |
|
2023-03-01 |
4 |
AS |
$18.61 |
$465,303 |
I/I |
(25,000) |
330,000 |
|
- |
|
York Charles N Ii |
COO, CFO and Secretary |
|
2023-02-17 |
4 |
AS |
$20.03 |
$187,790 |
D/D |
(9,377) |
262,128 |
|
- |
|
Blackman Samuel C. |
Chief Medical Officer |
|
2023-02-16 |
4 |
S |
$19.57 |
$13,192 |
D/D |
(674) |
1,243,660 |
|
- |
|
York Charles N Ii |
COO, CFO and Secretary |
|
2023-02-16 |
4 |
S |
$19.57 |
$18,203 |
D/D |
(930) |
271,505 |
|
- |
|
Bender Jeremy |
Chief Executive Officer |
|
2023-02-16 |
4 |
S |
$19.57 |
$59,150 |
D/D |
(3,022) |
1,186,776 |
|
- |
|
Blackman Samuel C. |
Chief Medical Officer |
|
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,624 |
1,244,334 |
|
- |
|
York Charles N Ii |
COO, CFO and Secretary |
|
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,625 |
272,435 |
|
- |
|
Bender Jeremy |
Chief Executive Officer |
|
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,312 |
1,189,798 |
|
- |
|
Blackman Samuel C. |
Chief Medical Officer |
|
2023-02-10 |
4 |
AS |
$20.07 |
$200,659 |
D/D |
(10,000) |
1,241,710 |
|
- |
|
Papanek Julie |
Director |
|
2023-02-01 |
4 |
AS |
$21.21 |
$530,794 |
I/I |
(25,000) |
355,000 |
|
- |
|
Bender Jeremy |
Chief Executive Officer |
|
2023-01-23 |
4 |
AS |
$22.00 |
$274,988 |
D/D |
(12,500) |
1,181,486 |
|
- |
|
York Charles N Ii |
COO, CFO and Secretary |
|
2023-01-20 |
4 |
AS |
$22.75 |
$227,523 |
D/D |
(10,000) |
268,810 |
|
- |
|
Blackman Samuel C. |
Chief Medical Officer |
|
2023-01-10 |
4 |
AS |
$22.75 |
$228,644 |
D/D |
(10,000) |
1,250,148 |
|
- |
|
Papanek Julie |
Director |
|
2023-01-03 |
4 |
AS |
$20.36 |
$516,147 |
I/I |
(25,000) |
380,000 |
|
- |
|
Bender Jeremy |
Chief Executive Officer |
|
2022-12-21 |
4 |
AS |
$20.32 |
$253,969 |
D/D |
(12,500) |
1,192,424 |
|
- |
|
183 Records found
|
|
Page 3 of 8 |
|
|